🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Wisconsin

Etid klinik pou Leksemi mieloïd egi nan Wisconsin

25 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan Wisconsin.

Vil nan Wisconsin

Tèks ofisyèl etid la (Anglè)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Gundersen Lutheran Medical Center, La Crosse
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • ak 50 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • ak 6 plis
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • ak 41 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • ak 11 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Duluth Clinic Ashland, Ashland
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
  • ak 9 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • ak 8 plis
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
  • ak 1 plis
Ap rekriteFaz 3
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

A Study of BGB-11417 in Participants With Myeloid Malignancies

  • Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT04771130

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Ap rekriteFaz 3
Laj 1 a 25 · Tout sèks · Mizajou Sep 4, 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Wisconsin, Madison
  • Froedtert & Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Froedtert & Medical College Clinics, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06656494

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Wisconsin - Madison, Madison
  • Children's Hospital of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

Ivosidenib as Post-HSCT Maintenance for AML

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jun 18, 2026 · NCT06707493

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • University of Wisconsin Carbone Cancer Center, Madison
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 14, 2026 · NCT06222580

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Froedtert & Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • University of Wisconsin Carbone Cancer Center, Madison
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Apr 22, 2026 · NCT05101551

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Wisconsin Hospital and Clinics, Madison
  • Medical College of Wisconsin Cancer Center, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184

Venetoclax to Augment Epigenetic Modification and Chemotherapy

  • Children's Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Jan 12, 2026 · NCT05317403

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • University of Wisconsin Carbone Cancer Center, Madison
Ap rekriteFaz 1
7 Months – 21 Years · Tout sèks · Mizajou Oct 16, 2025 · NCT02508038

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • University of Wisconsin Clinical Science Center, Madison
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • University of Wisconsin, Madison
Ap rekriteVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou Jul 25, 2025 · NCT05237258

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.